New insider activity at Rocket Pharmaceuticals ( (RCKT) ) has taken place on April 15, 2025.
CEO Gaurav Shah has made a significant investment in Rocket Pharmaceuticals by purchasing 20,000 shares of the company’s stock. This transaction is valued at $101,600, indicating a strong vote of confidence in the company’s future prospects.
Spark’s Take on RCKT Stock
According to Spark, TipRanks’ AI Analyst, RCKT is a Underperform.
Rocket Pharmaceuticals’ stock score reflects the high-risk nature of its business model as a biotechnology firm in the R&D phase. The company’s strong cash and equity positions are positive, but the lack of revenue and ongoing cash burn are significant concerns. The stock’s technical weakness further underscores the challenges, while its negative P/E ratio and absence of dividends highlight current profitability issues.
To see Spark’s full report on RCKT stock, click here.
More about Rocket Pharmaceuticals
YTD Price Performance: -58.57%
Average Trading Volume: 2,097,184
Technical Sentiment Signal: Strong Buy
Current Market Cap: $561.9M